Nextrials Introduces Industry’s First Automated Tracking and Electronic Notification System for Safety Trends in Ongoing Clinical Trials
Nextrials’ Prism® now offers enhanced reporting capabilities and additional safety features
San Ramon, CA -- May 17, 2005 -- Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism software now offers the industry's first electronic messaging system for identification and tracking of safety trends, providing researchers with early alerts of potentially significant safety developments. One of the most advanced Electronic Data Capture (EDC) products on the market, Prism's enhanced safety features give research professionals the ability to set threshold tolerance levels for investigational studies of biopharmaceuticals and medical devices. Researchers can then monitor these thresholds in real-time across multiple test sites and multiple studies, receiving electronic alerts when data trends point to potential safety concerns.
The new system solves two pressing problems for the industry by providing immediate access to data obtained across multiple project sites and studies while helping minimize public and financial risks when clinical data shows safety concerns.
"This new capability is in direct response to the industry's increasing focus on safety," notes James Rogers, co-founder and CEO of Nextrials. "Researchers have traditionally reviewed safety data on a periodic basis by analyzing data that is weeks or even months out-of-date. This delay exposes sponsors and patients to unnecessary risks. Prism's safety alert system provides life sciences companies with an early warning system for clinical trials that increases patient safety."
Prism's advanced data mining capability spots and analyzes multi-project safety trends, even in cases where the overall clinical trial remains below threshold levels, and electronically sends notification to researchers. This increases the industry's ability to conduct significant, complex clinical research in a safe and cost-effective environment.
Nextrials has also added international reporting capabilities to Prism, enabling pharmaceutical, biotechnology and medical device firms to more quickly comply with regulations for safety reporting in countries around the globe.
Visitors to the BIO-IT World Conference + Expo, held May 17-19 at the Hynes Convention Center in Boston, can view live demonstrations of Prism at Nextrials' booth #708.
About Nextrials, Inc.
Founded by pharmaceutical researchers in 1999, Nextrials offers today's most innovative products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism, its award-winning Electronic Data Capture (EDC) solution, has been used at over 200 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
